Solengepras Phase Three Trial Completion
A new daily medication named solengepras has successfully completed a late-stage clinical trial, marking a potential breakthrough for Parkinson’s disease treatment. Beyond managing motor symptoms, solengepras helped patients stay more alert during the day, simplified daily tasks like dressing and eating, and enhanced overall quality of life.
Non-Dopaminergic Mechanism
Solengepras operates through a completely different mechanism compared to treatments that have been central to Parkinson’s care for over fifty years. Traditional medications primarily target dopamine, a brain chemical messenger that diminishes as nerve cells die off in people with the condition. By reducing this braking effect, the drug aims to restore balance to the brain’s movement system.
Dame Kate Bingham, managing partner at SV Health Investors and a supporter of biotech company Cerevance, characterized the drug as an entirely new class beyond the dopamine pathway. Laurence Barker, a partner at SV Health Investors and a board member of Cerevance, noted that this study represents the first positive phase three trial for a non-dopaminergic mechanism in a very long time.
Impact on Patients in Australia
Parkinson’s is the second most common neurological condition in Australia, second only to dementia. About 10 to 20 percent of all individuals with Parkinson’s receive a diagnosis between their 20s and 50s, a classification known as Young Onset Parkinson’s, with more than 1,100 younger Australians developing it annually.
Traditional treatments like Levodopa, which revolutionized care in the 1960s by converting into dopamine in the body, can lose effectiveness as the disease advances. Patients frequently encounter off periods when medication effects fade and symptoms reappear, alongside potential complications like dyskinesia from involuntary movements.
Next Steps for Regulatory Review
The next steps for solengepras involve formal discussions with health regulators following the successful completion of the late-stage trial.
Keep reading